1. Home
  2. ATNM vs BAFN Comparison

ATNM vs BAFN Comparison

Compare ATNM & BAFN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ATNM
  • BAFN
  • Stock Information
  • Founded
  • ATNM 2000
  • BAFN 1999
  • Country
  • ATNM United States
  • BAFN United States
  • Employees
  • ATNM N/A
  • BAFN N/A
  • Industry
  • ATNM Biotechnology: Pharmaceutical Preparations
  • BAFN Savings Institutions
  • Sector
  • ATNM Health Care
  • BAFN Finance
  • Exchange
  • ATNM Nasdaq
  • BAFN Nasdaq
  • Market Cap
  • ATNM 50.2M
  • BAFN 40.6M
  • IPO Year
  • ATNM N/A
  • BAFN N/A
  • Fundamental
  • Price
  • ATNM $1.51
  • BAFN $9.50
  • Analyst Decision
  • ATNM Strong Buy
  • BAFN
  • Analyst Count
  • ATNM 2
  • BAFN 0
  • Target Price
  • ATNM $4.50
  • BAFN N/A
  • AVG Volume (30 Days)
  • ATNM 160.4K
  • BAFN 14.7K
  • Earning Date
  • ATNM 11-13-2025
  • BAFN 10-30-2025
  • Dividend Yield
  • ATNM N/A
  • BAFN 3.30%
  • EPS Growth
  • ATNM N/A
  • BAFN 100.65
  • EPS
  • ATNM N/A
  • BAFN 1.89
  • Revenue
  • ATNM N/A
  • BAFN $78,211,000.00
  • Revenue This Year
  • ATNM N/A
  • BAFN N/A
  • Revenue Next Year
  • ATNM N/A
  • BAFN N/A
  • P/E Ratio
  • ATNM N/A
  • BAFN $4.97
  • Revenue Growth
  • ATNM N/A
  • BAFN 0.67
  • 52 Week Low
  • ATNM $1.03
  • BAFN $6.40
  • 52 Week High
  • ATNM $2.41
  • BAFN $19.75
  • Technical
  • Relative Strength Index (RSI)
  • ATNM 43.91
  • BAFN 48.53
  • Support Level
  • ATNM $1.47
  • BAFN $9.38
  • Resistance Level
  • ATNM $1.59
  • BAFN $10.18
  • Average True Range (ATR)
  • ATNM 0.08
  • BAFN 0.39
  • MACD
  • ATNM -0.00
  • BAFN -0.05
  • Stochastic Oscillator
  • ATNM 28.95
  • BAFN 15.30

About ATNM Actinium Pharmaceuticals Inc. (Delaware)

Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications, and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.

About BAFN BayFirst Financial Corp.

BayFirst Financial Corp is a bank holding company, it generates its revenue from interest on loans and the gain-on-sale income derived from the sale of loans into the secondary market. The company serves a broad spectrum of individuals, families, and small businesses, supported by national business lines in residential and SBA lending and technology platforms. The primary source of funding for its loans is deposits. BayFirst measures performance through net interest income after provision for loan losses, return on average assets, and return on average common equity, while maintaining appropriate regulatory leverage and risk-based capital ratios. The company has various segment such as Real Estate(Residential, Commercial, and Construction & Land), Commercial and Industrial, Consumer.

Share on Social Networks: